Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionSlow Capital, Inc.
Latest Disclosed Ownership12,307 shares
Latest Disclosed Value $ 5,495,568
Slow Capital, Inc. reports 8.49% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 24, 2026 - Slow Capital, Inc. filed a 13F-HR form disclosing ownership of 12,307 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,495,568 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 11,344 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 8.49% during the quarter. The current value of the position is $5,271,580 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,307 963 8.49 5,496 6.87 0.7137
2026-01-26 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,344 44 0.39 5,143 16.20 0.6142
2025-10-29 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,300 -514 -4.35 4,426 -15.86 0.5200
2025-07-23 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,814 -20 -0.17 5,260 -8.33 0.6442
2025-05-02 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,834 198 1.70 5,737 22.45 0.7681
2025-01-22 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,636 -1,003 -7.94 4,686 -20.30 0.6633
2024-10-18 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,639 -26 -0.21 5,878 -0.98 0.9005
2024-07-24 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,665 -245 -1.90 5,936 10.01 0.9610
2024-04-17 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,910 -87 -0.67 5,397 2.04 0.8647
2024-01-31 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,997 51 0.39 5,288 17.49 0.9201
2023-10-19 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,946 690 5.63 4,502 4.36 0.8265
2023-08-09 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,256 -733 -5.64 4,313 5.40 0.7484
2023-04-26 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,989 2,809 27.59 4,092 39.23 0.7655
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,180 -264 -2.53 2,940 -2.81 0.6542
2022-10-27 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,444 283 2.79 3,024 5.62 0.6535
2022-07-28 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,161 -480 -4.51 2,863 3.10 0.6951
2022-05-02 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,641 -636 -5.64 2,777 12.16 0.5187
2022-02-08 2021-12-31 13F Vertex Pharmaceuticals COM 92532F100 11,277 -4,111 -26.72 2,476 -11.29 0.4231
2021-10-21 2021-09-30 13F Vertex Pharmaceuticals COM 92532F100 15,388 -44 -0.29 2,791 -10.31 0.5116
2021-07-29 2021-06-30 13F Vertex Pharmaceuticals COM 92532F100 15,432 3,033 24.46 3,112 13.99 0.5884
2021-05-20 2021-03-31 13F/A-1 Vertex Pharmaceuticals COM 92532F100 12,399 1,841 17.44 2,730 9.42 0.5924
2021-05-05 2021-03-31 13F Vertex Pharmaceuticals COM 92532F100 11,928 1,370 2,563 0.6240
2021-02-11 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 10,558 2,408 29.55 2,495 12.49 0.5965
2020-11-04 2020-09-30 13F Vertex Pharmaceuticals COM 92532F100 8,150 564 7.43 2,218 0.73 0.6042
2020-08-10 2020-06-30 13F Vertex Pharmaceuticals COM 92532F100 7,586 135 1.81 2,202 24.20 0.6464
2020-05-12 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 7,451 695 10.29 1,773 19.88 0.6694
2020-02-14 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 6,756 -246 -3.51 1,479 24.70 0.4573
2019-11-06 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 7,002 2,881 69.91 1,186 56.88 0.4194
2019-08-01 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 4,121 4,121 756 0.3119
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.